Innovative Protein Folding Predictions

A Revolutionary Breakthrough in Precision Medicine

Based on the leading science of Dr. Neil Cashman, our proprietary target discovery engine, EpiSelect™, utilizes computational discovery technologies to predict and identify toxic misfolded proteins implicated in the development and progression of neurodegenerative and other misfolded protein diseases.

About Our Science

A Growing Portfolio of Selective Antibody Therapeutic Product Candidates

Our portfolio leverages a revolutionary approach that enables the tailoring of therapeutic antibodies with a high degree of selectivity for the key drivers of multiple neurodegenerative and other misfolded protein diseases, including:

  • Alzheimer’s disease (AD)
  • Amyotrophic lateral sclerosis (ALS)
  • Frontotemporal dementia (FTD)
  • Multiple System Atrophy (MSA)
  • Parkinson’s disease (PD)
View Product Pipeline

Addressing Neurodegenerative and Other Misfolded Protein Diseases Using Novel Biologic Products

We are ProMIS Neurosciences, a leading clinical-stage biotechnology company based in Toronto, Ontario and Cambridge, Massachusetts. Our large team of multidisciplinary experts is committed to the discovery and development of selective antibody therapies that combat neurodegenerative and other misfolded protein diseases at the source.

About Our Company

Latest News

View All News

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference

View All News

Stock Snapshot